Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.”In the company’s words, NCT06239714 on ClinicalTrials.gov
- Tested for
- Hyperlipidemias
- Main trialPhase 1
- “This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered subcutaneously to subjects with elevated LDL-C to evaluate the safety, tolerance, PK, and PD.”In the company’s words, NCT06239714 on ClinicalTrials.gov
Other drugs for Hyperlipidemias
- ObicetrapibNewAmsterdam Pharma · Phase 3
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- SHR-1918Hengrui · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 18 Feb 2025 | A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026